- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eli Lilly and Company (LLY)
Eli Lilly and Company stock price live, this page displays NYSE LLY stock exchange data. View the LLY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eli Lilly and Company real time stock price chart below.
What Is the Eli Lilly and Company Stock Price Today?
The Eli Lilly and Company stock price today is 839.96.
What Is the Stock Symbol for Eli Lilly and Company?
The stock symbol for Eli Lilly and Company is "LLY."
What Stock Exchange Does Eli Lilly and Company Trade On?
Eli Lilly and Company is listed and trades on the NYSE stock exchange.
Is Eli Lilly and Company a Good Stock to Buy?
Determining whether Eli Lilly and Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LLY quote. (ISIN: US5324571083)
What Is the Eli Lilly and Company Stock Price Today?
The Eli Lilly and Company stock price today is 839.96.
What Is the Stock Symbol for Eli Lilly and Company?
The stock symbol for Eli Lilly and Company is "LLY."
What Stock Exchange Does Eli Lilly and Company Trade On?
Eli Lilly and Company is listed and trades on the NYSE stock exchange.
Is Eli Lilly and Company a Good Stock to Buy?
Determining whether Eli Lilly and Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LLY quote. (ISIN: US5324571083)
839.96
+105.06(+14.30%)
Closed·
Pre Market
843.97+4.01(+0.48%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
821.84
858.00
52 wk Range
677.09
972.53
LLY Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
821.84858.00
52 wk Range
677.09972.53
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.71%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.71%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LLY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
1,006.09
Upside
+19.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company SWOT Analysis
GLP-1 Market Leade | Eli Lilly dominates the GLP-1 category with Mounjaro and Zepbound, showcasing strong growth in prescriptions and market share against key competitors |
Global Expansion | Explore Eli Lilly's strategy to tap into ex-US markets, representing 90% of projected long-term volume for GLP-1 treatments, driving significant future growth |
Pipeline Potential | Delve into Eli Lilly's promising pipeline, including Orforglipron, an oral GLP-1 treatment that could revolutionize the market with its convenience and efficacy |
Financial Outlook | Analysts set price targets ranging from $970 to $1,250, reflecting optimism about Eli Lilly's 2025 revenue guidance of $58-$61 billion and robust 32% topline growth |
Compare LLY to Peers and Sector
Metrics to compare | LLY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLLYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 71.2x | 18.3x | −0.5x | |
PEG Ratio | 0.70 | 0.00 | 0.00 | |
Price/Book | 53.1x | 1.8x | 2.6x | |
Price / LTM Sales | 16.7x | 4.2x | 2.9x | |
Upside (Analyst Target) | 19.6% | 79.0% | 66.3% | |
Fair Value Upside | Unlock | 27.1% | 10.2% | Unlock |
Analyst Ratings
24 Buy
3 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1,006.09
(+19.78% Upside)
Earnings
Latest Release
Feb 06, 2025
EPS / Forecast
5.32 / 5.30
Revenue / Forecast
13.53B / 13.78B
People Also Watch
FAQ
What Is the Eli Lilly (LLY) Stock Price Today?
The Eli Lilly stock price today is 839.96
What Stock Exchange Does Eli Lilly Trade On?
Eli Lilly is listed and trades on the NYSE stock exchange.
What Is the Stock Symbol for Eli Lilly?
The stock symbol for Eli Lilly is "LLY."
Does Eli Lilly Pay Dividends? What’s The Current Dividend Yield?
The Eli Lilly dividend yield is 0.71%.
What Is the Eli Lilly Market Cap?
As of today, Eli Lilly market cap is 754.27B.
What is Eli Lilly Earnings Per Share?
The Eli Lilly EPS is 11.76.
What Is the Next Eli Lilly Earnings Date?
Eli Lilly will release its next earnings report on May 01, 2025.
From a Technical Analysis Perspective, Is LLY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.